Glenis Scadding
YOU?
Author Swipe
View article: Raising the bar in respiratory care by EUFOREA: report of the European Union Parliament Symposium, April 2024
Raising the bar in respiratory care by EUFOREA: report of the European Union Parliament Symposium, April 2024 Open
In April 2024, the European Summit “ Raising the bar in respiratory care” was organized by the European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) in the European Parliament and hosted by Members of the Europ…
View article: Pre-asthma: a useful concept? A EUFOREA paper. Part 2—late onset eosinophilic asthma
Pre-asthma: a useful concept? A EUFOREA paper. Part 2—late onset eosinophilic asthma Open
The concept of pre-diabetes has led to provision of measures to reduce disease progression through identification of subjects at risk of diabetes. We previously considered the idea of pre-asthma in relation to allergic asthma and considere…
View article: Why fexofenadine is considered as a truly non-sedating antihistamine with no brain penetration: a systematic review
Why fexofenadine is considered as a truly non-sedating antihistamine with no brain penetration: a systematic review Open
Published literature based on various parameters and clinical trials conducted for evaluating the effect of fexofenadine on sedation and central nervous system shows fexofenadine is both clinically effective and non-sedating.
View article: EUFOREUM Berlin 2023: Optimizing care for type 2 inflammatory diseases from clinic to AI: A pediatric focus
EUFOREUM Berlin 2023: Optimizing care for type 2 inflammatory diseases from clinic to AI: A pediatric focus Open
The European Forum for Research and Education in Allergy and Airways diseases (EUFOREA) organized its bi‐annual forum EUFOREUM in Berlin in November 2023. The aim of EUFOREUM 2023 was to highlight pediatric action plans for prevention and …
View article: Pre-asthma: a useful concept? A EUFOREA paper. Part 2—late onset eosinophilic asthma
Pre-asthma: a useful concept? A EUFOREA paper. Part 2—late onset eosinophilic asthma Open
The concept of pre-diabetes has led to provision of measures to reduce disease progression through identification of subjects at risk of diabetes. We previously considered the idea of pre-asthma in relation to allergic asthma and considere…
View article: Editorial: 2022 in review: rhinology
Editorial: 2022 in review: rhinology Open
status: Published
View article: Nasal polyp syndrome: a patient-centred term for CRSwNP by EUFOREA
Nasal polyp syndrome: a patient-centred term for CRSwNP by EUFOREA Open
Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) is a chronic inflammatory disease of the nose and paranasal sinus cavities that significantly affects well-being and social function, particularly in young adults and middle-aged population…
View article: Quality of Life in NSAIDs-Exacerbated Respiratory Disease on or off Intranasal Lysine Aspirin Therapy
Quality of Life in NSAIDs-Exacerbated Respiratory Disease on or off Intranasal Lysine Aspirin Therapy Open
Background: Intranasal administration of lysine aspirin (LAS) is a safe and effective method for aspirin treatment after desensitisation (ATAD). Changes in quality of life (QoL) in patients on intranasal LAS have not been documented and we…
View article: Pre-asthma: a useful concept for prevention and disease-modification? A EUFOREA paper. Part 1—allergic asthma
Pre-asthma: a useful concept for prevention and disease-modification? A EUFOREA paper. Part 1—allergic asthma Open
Asthma, which affects some 300 million people worldwide and caused 455,000 deaths in 2019, is a significant burden to suffers and to society. It is the most common chronic disease in children and represents one of the major causes for year…
View article: Pre-asthma: a useful concept for prevention and disease-modification? A EUFOREA paper. Part 1—allergic asthma
Pre-asthma: a useful concept for prevention and disease-modification? A EUFOREA paper. Part 1—allergic asthma Open
Asthma, which affects some 300 million people worldwide and caused 455,000 deaths in 2019, is a significant burden to suffers and to society. It is the most common chronic disease in children and represents one of the major causes for year…
View article: A EUFOREA Comment In Reference to <i>Cost‐Effectiveness Analysis of Inferior Turbinate Reduction and Immunotherapy in Allergic Rhinitis</i>
A EUFOREA Comment In Reference to <i>Cost‐Effectiveness Analysis of Inferior Turbinate Reduction and Immunotherapy in Allergic Rhinitis</i> Open
Dear Editor,\nThe EUFOREA Expert Panel on allergic rhinitis has read with interest the article by Yong et al.1 article and has concerns about the final conclusions.\n\nAlthough some patients were classified as non-responders, no considerat…
View article: EUFOREA/EPOS2020 statement on the clinical considerations for chronic rhinosinusitis with nasal polyps care
EUFOREA/EPOS2020 statement on the clinical considerations for chronic rhinosinusitis with nasal polyps care Open
Following the European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) treatment algorithm for chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP), patients suffering from severe uncontrolled CRSwNP are recomm…
View article: Is endoscopic sinus surgery sufficient to modify the evolution of adult AERD? Aspirin desensitization as a maintenance factor: systematic review
Is endoscopic sinus surgery sufficient to modify the evolution of adult AERD? Aspirin desensitization as a maintenance factor: systematic review Open
Introduction Aspirin desensitization (AD) and aspirin therapy after desensitization (ATAD) are therapeutic interventions for patients with aspirin-exacerbated respiratory disease (AERD). Our aim is to investigate whether its addition to en…
View article: EUFOREA pocket guide on the diagnosis and management of asthma: An educational and practical tool for general practitioners, non-respiratory physicians, paramedics and patients
EUFOREA pocket guide on the diagnosis and management of asthma: An educational and practical tool for general practitioners, non-respiratory physicians, paramedics and patients Open
Funding Information: Funding was provided via an unrestricted grant to EUFOREA by GlaxoSmithKline, Belgium .
View article: EUFOREA summit in Brussels 2023: inspiring the future of allergy & respiratory care
EUFOREA summit in Brussels 2023: inspiring the future of allergy & respiratory care Open
In March 2023, the European Forum for Research and Education in Allergy and Airways diseases (EUFOREA) organized its bi-annual Summit in Brussels with expert panel members of EUFOREA, representatives of the EUFOREA patient advisory board, …
View article: EUFOREA Comment on a Misleading Allergic Rhinitis Report [Letter]
EUFOREA Comment on a Misleading Allergic Rhinitis Report [Letter] Open
status: Published
View article: Editorial: Insights in rhinology: 2021/22
Editorial: Insights in rhinology: 2021/22 Open
EDITORIAL article Front. Allergy, 12 June 2023Sec. Rhinology Volume 4 - 2023 | https://doi.org/10.3389/falgy.2023.1221497
View article: Monoclonal antibody or aspirin desensitization in NSAID-exacerbated respiratory disease (N-ERD)?
Monoclonal antibody or aspirin desensitization in NSAID-exacerbated respiratory disease (N-ERD)? Open
Nonsteroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease (N-ERD) is a clinical syndrome characterized by nasal polyposis, asthma, and intolerance to aspirin/NSAID. It affects approximately 15% cases of severe asthma, 10%…
View article: European Academy of Allergy and Clinical Immunology position paper on endoscopic scoring of nasal polyposis
European Academy of Allergy and Clinical Immunology position paper on endoscopic scoring of nasal polyposis Open
Nasal endoscopy is not only used for the diagnosis of chronic rhinosinusitis with nasal polyps (CRSwNP), but also for monitoring the response to therapy playing an important role in both daily practice and research. In contrast to patient‐…
View article: Corrigendum on: White paper on European patient needs and suggestions on chronic type 2 inflammation of airways and skin by EUFOREA
Corrigendum on: White paper on European patient needs and suggestions on chronic type 2 inflammation of airways and skin by EUFOREA Open
[This corrects the article DOI: 10.3389/falgy.2022.889221.].
View article: White Paper on European Patient Needs and Suggestions on Chronic Type 2 Inflammation of Airways and Skin by EUFOREA
White Paper on European Patient Needs and Suggestions on Chronic Type 2 Inflammation of Airways and Skin by EUFOREA Open
Background Type 2 inflammation underlies the chronicity of disease in subgroups of patients with asthma, chronic rhinosinusitis with nasal polyps (CRSwNP) and atopic dermatitis (AD), that often co-exist. Although several studies have inves…
View article: A New Grand Challenge in Rhinology: An Intranasal COVID Vaccine
A New Grand Challenge in Rhinology: An Intranasal COVID Vaccine Open
OPINION article Front. Allergy, 20 May 2022Sec. Rhinology https://doi.org/10.3389/falgy.2022.881118
View article: Social and ethical factors in anaphylaxis
Social and ethical factors in anaphylaxis Open
Anaphylaxis has gained worldwide attention following allergic reactions to COVID vaccines.1 Guidelines have been renewed.2 The use of the International Classification of Diseases, 11th Revision (ICD-11), containing the first ever chapter a…
View article: Pathophysiological and Clinical Aspects of Chronic Rhinosinusitis: Current Concepts
Pathophysiological and Clinical Aspects of Chronic Rhinosinusitis: Current Concepts Open
Adult chronic rhinosinusitis (CRS) is a chronic inflammation of the mucosa of the nose and paranasal sinuses. According to the latest EPOS guidelines CRS should be regarded as primary or secondary with distinction between diffuse and local…
View article: A retrospective study on long-term efficacy of intranasal lysine-aspirin in controlling NSAID-exacerbated respiratory disease
A retrospective study on long-term efficacy of intranasal lysine-aspirin in controlling NSAID-exacerbated respiratory disease Open
Purpose Aspirin treatment after desensitization (ATAD) represents an effective therapeutic option suitable for NSAID-exacerbated respiratory disease (N-ERD) patients with recalcitrant disease. Intranasal administration of lysine-aspirin (L…